Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    April 2017
  1. LUI AJ, Geanes ES, Ogony J, Behbod F, et al
    IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
    Cancer Lett. 2017 Apr 12. pii: S0304-3835(17)30235.
    PubMed     Text format     Abstract available


    March 2017
  2. DESHMUKH SK, Srivastava SK, Zubair H, Bhardwaj A, et al
    Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes.
    Cancer Lett. 2017 Mar 13. pii: S0304-3835(17)30174.
    PubMed     Text format     Abstract available


  3. MONTEIRO FL, Vitorino R, Wang J, Cardoso H, et al
    The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.
    Cancer Lett. 2017 Mar 10. pii: S0304-3835(17)30171.
    PubMed     Text format     Abstract available


  4. LI Y, Li J, Zhang Y, Wang Y, et al
    Roles of Cancer/Testis Antigens (CTAs) in Breast Cancer.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30148.
    PubMed     Text format     Abstract available


    February 2017
  5. BURNETT JP, Lim G, Li Y, Shah RB, et al
    Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Cancer Lett. 2017 Feb 27. pii: S0304-3835(17)30132.
    PubMed     Text format     Abstract available


  6. ZHANG Z, Zhu Y, Wang Z, Zhang T, et al
    Yin-Yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30108.
    PubMed     Text format     Abstract available


    January 2017
  7. MONTAGNA E, Palazzo A, Maisonneuve P, Cancello G, et al
    Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Cancer Lett. 2017 Jan 26. pii: S0304-3835(17)30068.
    PubMed     Text format     Abstract available


  8. RESZKA E, Przybek M, Muurlink O, Peplonska B, et al
    Circadian gene variants and breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30035.
    PubMed     Text format     Abstract available


  9. BUI QT, Im JH, Jeong SB, Kim YM, et al
    Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30037.
    PubMed     Text format     Abstract available


  10. MENDOZA-RODRIGUEZ M, Romero HA, Fuentes-Panana EM, Ayala-Sumuano JT, et al
    IL-1beta induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30025.
    PubMed     Text format     Abstract available


  11. MUNZONE E, Colleoni M
    Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30026.
    PubMed     Text format     Abstract available


  12. HUANG R, Yu Y, Zong X, Li X, et al
    Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1alpha.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30020.
    PubMed     Text format     Abstract available


    December 2016
  13. BHARTI R, Dey G, Banerjee I, Dey KK, et al
    Somatostatin Receptor Targeted Liposomes with Diacerein Inhibit IL-6 for Breast Cancer Therapy.
    Cancer Lett. 2016 Dec 23. pii: S0304-3835(16)30784.
    PubMed     Text format     Abstract available


  14. CAZZANIGA ME, Dionisio MR, Riva F
    Metronomic chemotherapy for advanced breast cancer patients.
    Cancer Lett. 2016 Dec 23. pii: S0304-3835(16)30782.
    PubMed     Text format     Abstract available


  15. MULUHNGWI P, Krishna A, Vittitow SL, Napier JT, et al
    Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
    Cancer Lett. 2016;388:230-238.
    PubMed     Text format     Abstract available


    November 2016
  16. KIM JY, Lee N, Kim YJ, Cho Y, et al
    Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
    Cancer Lett. 2016 Nov 25. pii: S0304-3835(16)30710.
    PubMed     Text format     Abstract available


  17. TU M, Li Z, Liu X, Lv N, et al
    Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor beta 1 and hypoxia dependent repression of GATA-binding factor 3.
    Cancer Lett. 2016 Nov 17. pii: S0304-3835(16)30704.
    PubMed     Text format     Abstract available


  18. ZYSK A, DeNichilo MO, Panagopoulos V, Zinonos I, et al
    Adoptive transfer of ex vivo expanded Vgamma9Vdelta2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Cancer Lett. 2016 Nov 16. pii: S0304-3835(16)30699.
    PubMed     Text format     Abstract available


  19. LIANG YK, Zeng, Xiao YS, Wu Y, et al
    MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERalpha expression and AKT activation.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30682.
    PubMed     Text format     Abstract available


  20. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30681.
    PubMed     Text format     Abstract available


  21. JI X, Peng Z, Li X, Yan Z, et al
    Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
    Cancer Lett. 2016 Nov 7. pii: S0304-3835(16)30662.
    PubMed     Text format     Abstract available


    October 2016
  22. WANG X, Wei S, Zhao Y, Shi C, et al
    Anti-proliferation of breast cancer cells with itraconazole: hedgehog pathway inhibition induces apoptosis and autophagic cell death.
    Cancer Lett. 2016 Oct 31. pii: S0304-3835(16)30665.
    PubMed     Text format     Abstract available


  23. VENNIN C, Spruyt N, Robin YM, Chassat T, et al
    The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.
    Cancer Lett. 2016 Oct 22. pii: S0304-3835(16)30644.
    PubMed     Text format     Abstract available


  24. KIKUCHI M, Katoh H, Waraya M, Tanaka Y, et al
    Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
    Cancer Lett. 2016 Oct 15. pii: S0304-3835(16)30629.
    PubMed     Text format     Abstract available


  25. MIMOTO R, Nihira NT, Hirooka S, Takeyama H, et al
    Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Cancer Lett. 2016 Oct 13. pii: S0304-3835(16)30627.
    PubMed     Text format     Abstract available


  26. TU M, Lu C, Lv N, Wei J, et al
    Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2.
    Cancer Lett. 2016 Oct 1. pii: S0304-3835(16)30573.
    PubMed     Text format     Abstract available


    September 2016
  27. DI MODICA M, Regondi V, Sandri M, Iorio MV, et al
    Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30555.
    PubMed     Text format     Abstract available


  28. XU J, Han M, Shen J, Guan Q, et al
    2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30553.
    PubMed     Text format     Abstract available


  29. ZHU J, Zhou Q, Tan S
    Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30563.
    PubMed     Text format     Abstract available


  30. ZHANG Y, Zhang J, Liu C, Du S, et al
    Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Cancer Lett. 2016 Sep 2. pii: S0304-3835(16)30511.
    PubMed     Text format     Abstract available


    July 2016
  31. MARZEC KA, Martino-Echarri E, Irminger-Finger I, Henderson BR, et al
    BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.
    Cancer Lett. 2016 Jul 28. pii: S0304-3835(16)30453.
    PubMed     Text format     Abstract available


  32. PLUCHINO LA, Choudhary S, Wang HR
    Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
    Cancer Lett. 2016 Jul 28. pii: S0304-3835(16)30455.
    PubMed     Text format     Abstract available


  33. GARI HH, DeGala GD, Ray R, Lucia MS, et al
    PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
    Cancer Lett. 2016;380:505-512.
    PubMed     Text format     Abstract available


  34. PAVLOPOULOU A, Oktay Y, Vougas K, Louka M, et al
    Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
    Cancer Lett. 2016;380:485-493.
    PubMed     Text format     Abstract available


  35. UGOLKOV A, Gaisina I, Zhang JS, Billadeau DD, et al
    GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Cancer Lett. 2016 Jul 14. pii: S0304-3835(16)30400.
    PubMed     Text format     Abstract available


  36. ROSSETTI S, Bshara W, Reiners JA, Corlazzoli F, et al
    Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer.
    Cancer Lett. 2016 Jul 13. pii: S0304-3835(16)30397.
    PubMed     Text format     Abstract available


  37. WU J, Ding Y, Chen CH, Zhou Z, et al
    A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Cancer Lett. 2016 Jul 4. pii: S0304-3835(16)30393.
    PubMed     Text format     Abstract available


    June 2016
  38. LI XQ, Lu JT, Tan CC, Wang QS, et al
    RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization.
    Cancer Lett. 2016 Jun 15. pii: S0304-3835(16)30367.
    PubMed     Text format     Abstract available


  39. BAPU D, Runions J, Kadhim M, Brooks SA, et al
    N-acetylgalactosamine glycans function in cancer cell adhesion to endothelial cells: A role for truncated O-glycans in metastatic mechanisms.
    Cancer Lett. 2016;375:367-74.
    PubMed     Text format     Abstract available


  40. CHEN KH, Walker AM
    Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    Cancer Lett. 2016;375:293-302.
    PubMed     Text format     Abstract available


    May 2016
  41. KIM JY, Cho Y, Oh E, Lee N, et al
    Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Cancer Lett. 2016 May 26. pii: S0304-3835(16)30339.
    PubMed     Text format     Abstract available


  42. SASAKI S, Baba T, Nishimura T, Hayakawa Y, et al
    Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis.
    Cancer Lett. 2016;378:23-32.
    PubMed     Text format     Abstract available


  43. NUTA O, Somaiah N, Boyle S, Chua ML, et al
    Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
    Cancer Lett. 2016;374:324-30.
    PubMed     Text format     Abstract available


    April 2016
  44. REN Y, Zhou X, Liu X, Jia HH, et al
    Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
    Cancer Lett. 2016;374:96-106.
    PubMed     Text format     Abstract available


  45. KUANG XY, Jiang HS, Li K, Zheng YZ, et al
    The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis.
    Cancer Lett. 2016;377:87-96.
    PubMed     Text format     Abstract available


  46. LIU B, Zhang X, Song F, Zheng H, et al
    Mir-502/SET8 regulatory circuit in pathobiology of breast cancer.
    Cancer Lett. 2016 Apr 11. pii: S0304-3835(16)30221.
    PubMed     Text format     Abstract available


  47. YU C, Tang W, Wang Y, Shen Q, et al
    Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30219.
    PubMed     Text format     Abstract available


  48. WU J, Zhang S, Shan J, Hu Z, et al
    Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30218.
    PubMed     Text format     Abstract available


  49. LI Z, Zhu Q, Chen H, Hu L, et al
    Binding of anterior gradient 2 and estrogen receptor-alpha: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30216.
    PubMed     Text format     Abstract available


  50. LIANG DH, Choi DS, Ensor JE, Kaipparettu BA, et al
    The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30215.
    PubMed     Text format     Abstract available


  51. MALTONI R, Gallerani G, Fici P, Rocca A, et al
    CTCs in early breast cancer: A path worth taking.
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30212.
    PubMed     Text format     Abstract available


    March 2016
  52. LIU J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, et al
    GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30198.
    PubMed     Text format     Abstract available


  53. RIGALLI JP, Tocchetti GN, Arana MR, Villanueva SS, et al
    The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters.
    Cancer Lett. 2016 Mar 23. pii: S0304-3835(16)30200.
    PubMed     Text format     Abstract available


  54. BRANTLEY E, Callero MA, Berardi DE, Campbell P, et al
    AhR ligand Aminoflavone inhibits alpha6-integrin expression and breast cancer sphere-initiating capacity.
    Cancer Lett. 2016 Mar 17. pii: S0304-3835(16)30175.
    PubMed     Text format     Abstract available


  55. AMPUJA M, Alarmo EL, Owens P, Havunen R, et al
    The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model.
    Cancer Lett. 2016 Mar 9. pii: S0304-3835(16)30145.
    PubMed     Text format     Abstract available


  56. GOBEL A, Thiele S, Browne AJ, Rauner M, et al
    Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2016 Mar 8. pii: S0304-3835(16)30140.
    PubMed     Text format     Abstract available


  57. JUDES G, Rifai K, Daures M, Dubois L, et al
    High-throughput << Omics >> technologies: New tools for the study of triple-negative breast cancer.
    Cancer Lett. 2016 Mar 7. pii: S0304-3835(16)30137.
    PubMed     Text format     Abstract available


  58. LV W, Chen N, Lin Y, Ma Y, et al
    Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis.
    Cancer Lett. 2016 Mar 4. pii: S0304-3835(16)30051.
    PubMed     Text format     Abstract available


  59. ROWSON-HODEL AR, Berg AL, Wald JH, Hatakeyama J, et al
    Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
    Cancer Lett. 2016 Mar 2. pii: S0304-3835(16)30120.
    PubMed     Text format     Abstract available


  60. JACOB J, Favicchio R, Karimian N, Mehrabi M, et al
    LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.
    Cancer Lett. 2016;372:137-46.
    PubMed     Text format     Abstract available


  61. JAKHAR R, Paul S, Bhardwaj M, Kang SC, et al
    Astemizole-Histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis.
    Cancer Lett. 2016;372:89-100.
    PubMed     Text format     Abstract available


  62. XU Z, Wang Z, Jia X, Wang L, et al
    MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Cancer Lett. 2016;372:118-27.
    PubMed     Text format     Abstract available


    February 2016
  63. KIM PY, Tan O, Liu B, Trahair T, et al
    High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.
    Cancer Lett. 2016 Feb 19. pii: S0304-3835(16)30075.
    PubMed     Text format     Abstract available


  64. KAWPRASERTSRI S, Pietras RJ, Marguez-Garban DC, Boonyaratanakornkit V, et al
    Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.
    Cancer Lett. 2016 Feb 15. pii: S0304-3835(16)30068.
    PubMed     Text format     Abstract available


  65. GREK CL, Rhett JM, Bruce JS, Ghatnekar GS, et al
    Connexin 43, breast cancer tumor suppressor: missed connections?
    Cancer Lett. 2016 Feb 13. pii: S0304-3835(16)30062.
    PubMed     Text format     Abstract available


    January 2016
  66. AMOURY M, Kolberg K, Pham AT, Hristodorov D, et al
    Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Cancer Lett. 2016 Jan 21. pii: S0304-3835(16)00039.
    PubMed     Text format     Abstract available


  67. LUO M, Hou L, Li J, Shao S, et al
    VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin.
    Cancer Lett. 2016 Jan 19. pii: S0304-3835(16)00022.
    PubMed     Text format     Abstract available


  68. SHARMA MC, Tuszynski GP, Blackman MR, Sharma M, et al
    Long-term efficacy and downstream mechanism of anti-annexina2 monoclonal antibody (anti-ANX a2 mAb) in a pre-clinical model of aggressive human breast cancer.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00025.
    PubMed     Text format     Abstract available


  69. SHARMA B, Varney ML, Saxena S, Wu L, et al
    Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
    Cancer Lett. 2016 Jan 12. pii: S0304-3835(15)00750.
    PubMed     Text format     Abstract available


  70. SUYAMA K, Onishi H, Imaizumi A, Shinkai K, et al
    CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells.
    Cancer Lett. 2016 Jan 12. pii: S0304-3835(15)00754.
    PubMed     Text format     Abstract available


    December 2015
  71. LEE DH, Jung Jung Y, Koh D, Lim Y, et al
    A synthetic chalcone, 2'-hydroxy-2,3,5'-trimethoxychalcone triggers unfolded protein response-mediated apoptosis in breast cancer cells.
    Cancer Lett. 2015 Dec 29. pii: S0304-3835(15)00768.
    PubMed     Text format     Abstract available


  72. KOUSHYAR S, Jiang WG, Dart DA
    Unveiling the potential of prohibitin in cancer.
    Cancer Lett. 2015;369:316-22.
    PubMed     Text format     Abstract available


  73. HUNG AC, Tsai CH, Hou MF, Chang WL, et al
    The synthetic beta-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
    Cancer Lett. 2015 Dec 9. pii: S0304-3835(15)00725.
    PubMed     Text format     Abstract available


  74. STRECKER TE, Odutola SO, Lopez R, Cooper MS, et al
    The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.
    Cancer Lett. 2015;369:229-41.
    PubMed     Text format     Abstract available


    November 2015
  75. PATEL JS, Hu M, Sinha G, Walker ND, et al
    Non-coding RNA as mediators in microenvironment-breast cancer cell communication.
    Cancer Lett. 2015 Nov 12. pii: S0304-3835(15)00690.
    PubMed     Text format     Abstract available


  76. URSINI-SIEGEL J, Siegel PM
    The influence of the pre-metastatic niche on breast cancer metastasis.
    Cancer Lett. 2015 Nov 11. pii: S0304-3835(15)00683.
    PubMed     Text format     Abstract available


  77. WALKER ND, Patel J, Munoz JL, Hu M, et al
    The bone marrow niche in support of breast cancer dormancy.
    Cancer Lett. 2015 Nov 3. pii: S0304-3835(15)00664.
    PubMed     Text format     Abstract available


  78. ALASMAEL N, Mohan R, Meira LB, Swales KE, et al
    Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential.
    Cancer Lett. 2015 Nov 3. pii: S0304-3835(15)00662.
    PubMed     Text format     Abstract available


  79. HE T, Qi F, Jia L, Wang S, et al
    Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p.
    Cancer Lett. 2015;368:115-25.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: